Search Results - "Foà’, Robin"

Refine Results
  1. 1

    Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia by Foà, Robin, Chiaretti, Sabina

    Published in The New England journal of medicine (23-06-2022)
    “…Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids,…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? by Chiaretti, Sabina, Messina, Monica, Foà, Robin

    Published in Cancer (15-01-2019)
    “…BCR/ABL1–like acute lymphoblastic leukemia (ALL) accounts for 15% to 30% of B‐lineage ALL, with a peak of incidence occurring in adolescence. This subgroup of…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience by Salles, Gilles, Barrett, Martin, Foà, Robin, Maurer, Joerg, O’Brien, Susan, Valente, Nancy, Wenger, Michael, Maloney, David G.

    Published in Advances in therapy (01-10-2017)
    “…Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with…”
    Get full text
    Journal Article
  7. 7

    Childhood aggressive B‐cell non‐Hodgkin lymphoma in low–middle‐income countries by Moleti, Maria Luisa, Testi, Anna Maria, Foà, Robin

    Published in British journal of haematology (01-02-2022)
    “…Summary In high‐income countries (HICs) paediatric aggressive B‐cell lymphomas are curable in about 90% of cases. Much worse results, with cure rates ranging…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    Management of adult Ph-positive acute lymphoblastic leukemia by Chiaretti, Sabina, Foà, Robin

    Published in Hematology (05-12-2015)
    “…Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) has been regarded for decades as the ALL subgroup with the worse outcome. It represents the most…”
    Get full text
    Journal Article
  12. 12

    Changes in the Treatment Landscape for Chronic Lymphoid Leukemia by Foà, Robin

    Published in The New England journal of medicine (17-07-2014)
    “…After decades during which the treatment of patients with chronic lymphoid leukemia (CLL) was based on chemotherapy and more recently on chemoimmunotherapy, we…”
    Get full text
    Journal Article
  13. 13

    Treatment of relapsed/refractory paediatric aggressive B‐cell non‐Hodgkin lymphoma by Moleti, Maria L., Testi, Anna M., Foà, Robin

    Published in British journal of haematology (01-06-2020)
    “…Summary Aggressive B‐cell non‐Hodgkin lymphoma (B‐NHL) accounts for ≈60% of NHL in children/adolescents. In newly diagnosed Burkitt lymphoma and diffuse large…”
    Get full text
    Journal Article
  14. 14
  15. 15
  16. 16

    PSGL-1 decorated with sialyl Lewisa/x promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement by O’Dwyer, Michael, Kirkham-McCarthy, Lucy, Cerreto, Marina, Foà, Robin, Natoni, Alessandro

    Published in Scientific reports (19-01-2024)
    “…Dissemination of multiple myeloma into the bone marrow proceeds through sequential steps mediated by a variety of adhesion molecules and chemokines that…”
    Get full text
    Journal Article
  17. 17

    Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia by Breccia, Massimo, Foà, Robin

    Published in Current oncology reports (01-03-2018)
    “…Purpose of Review Discontinuation of tyrosine kinase inhibitors (TKIs) in chronic phase chronic myeloid leukemia (CP-CML) patients has become a reality…”
    Get full text
    Journal Article
  18. 18
  19. 19

    The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia by Cerreto, Marina, Foà, Robin, Natoni, Alessandro

    Published in Cancers (01-11-2023)
    “…Chronic lymphocytic leukemia (CLL) is a B-cell malignancy whose progression largely depends on the lymph node and bone marrow microenvironment. Indeed, CLL…”
    Get full text
    Journal Article
  20. 20